Log In
BCIQ
Print this Print this
 

Somatoprim (COR-005, DG3173)

  Manage Alerts
Collapse Summary General Information
Company Strongbridge Biopharma plc
DescriptionSomatostatin analog that suppresses human growth hormone (hGH) secretion by targeting somatostatin receptors 2, 4 and 5
Molecular Target Somatostatin receptor 2 (SSTR2) ; Somatostatin receptor 4 (SSTR4)
Mechanism of Action 
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase II
Standard IndicationAcromegaly
Indication DetailsTreat acromegaly
Regulatory Designation U.S. - Orphan Drug (Treat acromegaly);
EU - Orphan Drug (Treat acromegaly)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$30.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/15/2015

$30.0M

0

0

Get a free BioCentury trial today